Has anyone had a Targeted test for your bile duct cancer.

CholangiocarcinomaNovember 18, 2026Written by Navis AI

Yes, targeted testing is a standard part of care for bile duct cancer (cholangiocarcinoma). It's often called tumor biomarker testing, molecular profiling, or tumor mutation testing. I can't speak to individual patients' personal experiences, but I can explain what the testing involves and what the NCCN Guidelines for Patients: Gallbladder and Bile Duct Cancers (2026) say about it.

What is targeted (molecular) testing? A sample of your tumor, or sometimes a blood sample, is analyzed to look for specific gene changes (mutations) or other molecular features in the cancer cells. This is separate from hereditary genetic testing, which looks for mutations you may have inherited from your parents.

What are doctors looking for? According to NCCN, some findings can be matched to specific targeted therapies:

  • FGFR2 gene fusions or rearrangements
  • IDH1 mutations
  • BRAF V600E mutations
  • NTRK gene fusions
  • RET gene fusions
  • MSI-H/dMMR (microsatellite instability-high / mismatch repair deficient), which describes tumors with a high number of mutations, often tested with MSI/MMR testing
  • HER2, which appears in the list of therapies used in certain cases

When is it done? NCCN notes that for tumors that cannot be removed with surgery or that have spread (metastatic), MSI/MMR testing and other biomarker testing will be done. Testing may also be considered if the cancer progresses during or after treatment, since NCCN lists targeted drug options for that situation. A biopsy sample or blood draw is used. For some people, the first tissue available comes from surgery rather than a separate biopsy.

Why it matters NCCN lists several targeted and immunotherapy drugs used in certain cases, matched to specific findings. Examples include pemigatinib (Pemazyre) and futibatinib (Lytgobi) for FGFR2 changes, ivosidenib (Tibsovo) for IDH1 mutations, dabrafenib with trametinib for BRAF V600E, and larotrectinib or entrectinib for NTRK fusions. The guidelines also include immunotherapy options such as pembrolizumab and nivolumab. Whether any of these apply depends entirely on your specific test results, and your oncologist makes that determination.

Questions to ask your care team

  1. Has my tumor had molecular or biomarker testing, and if not, can it be ordered?
  2. Will testing use my tumor tissue, a blood sample, or both?
  3. Which genes or markers are included in the panel (such as FGFR2, IDH1, BRAF, NTRK, MSI/MMR)?
  4. How long will results take, and who will explain them to me?
  5. If a mutation is found, what treatment or clinical trial options might that open up for me?

If you've already had testing, feel free to share your report and I can help explain the terms in plain language.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your next question, already answered

Tap to keep going. 2 free answers, then a free account.

Ask Navis about your case

That answer is general. Ask about your specific situation. Answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

  • Built by OpenCancer’s team of physician-scientists and cancer survivors.
  • Last updated November 18, 2026. Informational only — not a substitute for your oncology team.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

More questions about Cholangiocarcinoma